This analysis, together with the genetic information from whole-exome and transcriptome sequencing, such as the presence of fusions diagnostic of other SGT types (described below), resulted in an analysis cohort of 43 cases (Table 1), each with matched normal tissue, including 32 BCAs, 9 BCACs and 2 SGTs with a differential diagnosis of BCAC and epithelial-myoepithelial carcinoma (BCAC/EMC) due to the presence of the oncogenic HRAS p.Q61R mutation (Supplementary Fig. 1). The gene discussed is HRAS; the disease is extraskeletal myxoid chondrosarcoma.